Manufacturer
3 recalls in our database name Valor Compounding Pharmacy, Inc DBA Valor Compounding Pharmacy as the manufacturing or recalling firm.
Of the 3 recalls from Valor Compounding Pharmacy, Inc DBA Valor Compounding Pharmacy we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 3 (100%) are Severe.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Valor Compounding Pharmacy is recalling Nifedipine WSP 0.2% Ointment due to potency variability. Some batches may be subpotent or superpotent, affecting safety and efficacy.
Valor Compounding Pharmacy recalls compounded Tacrolimus 0.5 mg/mL suspension due to subpotency. The medication, distributed in California, may not provide adequate therapeutic levels for immunosuppression in transplant patients.
Valor Compounding Pharmacy issued a Class I recall for compounded Tacrolimus suspension (Lot 04272022@35) distributed in California due to subpotency.